



Annual Meeting

Göttingen

12- 14 June 2008

Congress President

Jürgen Brockmüller, Göttingen

Scientific Committee:

Max Scheulen, Essen
Ralf A. Hilger, Essen
Robert Mader, Wien
Iduna Fichtner, Berlin
Michaela Arndt, Essen
Daniel Sehr, Göttingen

Local Organization:

Daniel Sehr, Göttingen
Cordula Sachse-Seeboth, Göttingen
Lorenz Trümper, Göttingen
Friedrich Hess, Göttingen
Günter Emons, Göttingen

Universitätsmedizin Göttingen
Georg-August-Universität
Robert-Koch-Strasse 40
37075 Göttingen
Germany

Participating Working Groups:

New Drug Development in Oncology AWO
Pharmacology and Haematology in Oncology APOH
Phase I-III
Clinical Pharmacology & GRK 1034 Göttingen

Meeting Venue:

Max-Planck-Institute for Experimental Medicine
Hermann-Rein-Strasse 3
37075 Göttingen
Germany

Online Registration:

www.cesar.or.at

Facing the Challenge of Drug Development in Oncology

Thursday, June 12, 2008

- 13:00 – 13:30 Welcome and Opening Remarks
- 13:30 – 15:00 **Resistance Mechanisms, Barriers to Successful Therapy**
(Workshop APOH)
Chairpersons: Ralf A. Hilger, Robert Mader
- Classical Resistance Mechanisms**
Walter Jäger, Vienna
- Molecular Resistance Mechanisms**
Robert Mader, Vienna
- Resistance to Targeted Therapies**
Doriano Fabbro, Basel
- 15:00 – 15:30 *Coffee Break*
- 15:30 – 17:00 **Individualized Drug Therapy: The Silver Bullet for Optimizing
Treatments in Oncology?** (Workshop Clinical Pharmacology)
Chairpersons: Jürgen Brockmüller, Daniel Seht
- Predicting Drug Response and Toxicity Based on Gene
Polymorphisms**
Jacques Robert, Bordeaux
- Die Rolle der Biomarker als Surrogatendpunkte / The Role of
Biomarkers as Clinical Surrogate Endpoints**
Max E. Scheulen, Essen
- Individually Optimized Cancer Chemotherapy**
Jürgen Brockmüller, Göttingen
- 17:45 – 22:00 **CESAR Executive Board Meeting**

Friday, June 13, 2008

- 08:30 – 09:00 *Coffee*
- 09:00 – 10:30 **From Drug Discovery to Clinical Application (I):
Lead Molecule to GMP Product** (Workshop AWO)
Chairpersons: Iduna Fichtner, Matthias Tacke
- Developing Small Molecules: From Discovery to GMP Production**
Bernhard Böhm, Biberach/Riss
- Developing Biologics: From Discovery to GMP Production**
Olivier Jankowitsch, Wien
- Rational Synthesis and Preclinical Characterization of a Novel
Natural Compound for Tubulin Targeted Therapy**
Jens Hoffman, Berlin
- 10:30 – 11:00 *Coffee Break*
- 11:00 – 12:00 **From Drug Discovery to Clinical Application (II):
Pre-Clinical Development to Phase I** (Workshop AWO)
Chairpersons: Michaela Arndt, Klaus Mross
- EMA Requirements on Pre-Clinical Evaluation of Anticancer
Medicinal Products**
Silvio Wuschko, Seibersdorf
- Challenges of Early Clinical Development in Oncology**
Bernhard Hauns, Konstanz
- 12:00 – 14:30 **Generalversammlung CESAR-D, CESAR-A und CESAR-EWIV
Business Meeting Phase I-III Working Groups**
Möglichkeit zur Vorstellung neuer Mitgliedsbewerber / Presentation of
applicants for CESAR membership
- Lunch Break*
- 14:30 – 15:15 **Innovative Medicines Initiative (IMI) – Research Grants for
European Public-Private Collaborations**
Karen Strandgaard, Brussels
- 15:15 – 15:45 *Coffee Break*
- 15:45 – 17:00 **Sitzung der Phase I-III Arbeitsgruppen**
Chairpersons: Klaus Mross, Christian Dittrich, Rudolf Morant
- “First-in-man“ Studien in der Onkologie / First-in-man trials in
Oncology**
Klaus Mross, Freiburg
- Update Klinische Studien / Update Clinical Trials**
- 19:30 **Conference Dinner (Deutsches Theater, Göttingen)**

Saturday, June 14, 2008

09:00 – 09:30 Coffee

09:30 – 11:00 **Freie Vorträge I / Young Scientist Presentations I**

Chairpersons: Max Scheulen, Ulrich Jaehde

Characterisation of transcriptional regulation of 5-HT_{3B} in rat PC-12 cells

Kristin Bokelmann, Mladen Tzvetkov, Jürgen Brockmüller

Transfection of HSP70 reduces the tumorigenicity of a HSP70-defective rat myeloma cell line

Sara Y. Demiroglu, Leslie Elsner, Vijayakumar Muppala, Thomas Herrmann, Ralf Dressel

A novel molecular mechanism of primary resistance to FLT3 kinase inhibitors in acute myeloid leukaemia (AML): Formation of FLT3-ITD627E and modulation of MCL-1

Frank Breitenbuecher, Boyka Markova, Stefan Kasper, Birgit Carius, Torsten Stauder, Thomas Kindler, Christoph Huber, Thomas Fischer

Combining Conventional Chemotherapy with Protein-Kinase-C Inhibitor PKC412 leads to Unpredictable Outcomes in NSCLC

Johannes A. Meiler, M. Guyot, S. Hoffarth, E. Wesarg, Y. Höhn, M. Schuler

Histone deacetylase inhibitors in Gastrointestinal stromal tumors (GIST) – disease specific effects and therapeutic potential

Thomas Mühlenberg, Jonathan Alfred Fletcher, Christian Hosius, Martin Schuler, Sebastian Bauer

Cyclosporin A but not everolimus inhibits DNA repair in human fibroblasts and lymphoblasts

Christiane Kuschal, Kai-Martin Thoms, Toshio Mori, Nobuhiko Kobayashi, Lars Boeckmann, Petra Laspe, Steffen Emmert

11.00 – 11.20 *Coffee Break*

11:20 – 12:50

Freie Vorträge II / Young Scientist Presentations II

Chairpersons: Max Scheulen, Ulrich Jaehde

Titanocene Y: A Janus-Headed Bioorganometallic Anticancer Drug

Matthias Tacke

Targeted therapies of *Hh*-associated cancers result in effective tumor prevention, but not in growth inhibition or regression of already established tumors

Ines Ecke, Fauke Petry, Albert Rosenberger, Christian Dullin, Judith Pirngruber, Steven A. Johnsen, Sarah Kimmina, Walter Schulz-Schaeffer, Olaf Witt, Heidi Hahn

Influence of organic cation transporters (OCT) on the uptake of oxaliplatin

Irina Buß, Ganna V. Kalayda, Ulrich Jaehde

Expression of EGFR-ligands in non small cell lung cancer xenograft models

Maria Rivera, Jana Rolff, Iduna Fichtner

Pharmacokinetic study of S-1

Bastian Mende, Ralf A. Hilger, Jürgen Krauss, Dagmar Thyssen, Susanne Kredtke, Max E. Scheulen, Dirk Strumberg, Axel Hanauske, Lukas Makris, Paul Scigalla, Peter D. Urrea

Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx™ (Doxil®)

Heike Richly, Matthias Grubert, Detlef Hecker, Max E. Scheulen, Ralf A. Hilger

12:50 – 13:00

Closing Remarks

13.00 – 13.40

Farewell Lunch



Posters

Modulation of the efficacy of temozolomide or dacarbazine melanoma treatment by DNA-repair factors *in vivo* and *in vitro*.

Lars Boeckmann, Kai-Martin Thoms, Ralf Gutzmer, Christina Has, Manfred Kunz, Ann-Christin Nickel, Christiane Kuschal, Petra Laspe, Diana Struever, Juergen Thomale, Steffen Emmert

Oxaliplatin Pharmacokinetics in Patients with Severe Hepatic Dysfunction

Anne Drescher, Martina Baur, Margit Gneist, Christian Dittrich, Ulrich Jaehde

Pharmacokinetic Study of Sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]-indazole hydrochloride (1:1.1) (FFC14A) in Patients with Solid Tumours

Magdalena M. Henke, Heike Richly, Matthias Grubert, Dennis Alex, Dagmar Thyssen, U. Jaehde, Max E. Scheulen, Ralf A. Hilger

Antitumoral *in vitro* activity of a new silver(I) complex

Ralf A. Hilger, Dennis Alex, Alexandra Heidemann, Malachy McCann, Kevin Kavanagh, Michael Devereux, Denise Egan

Chemosensitivity of uveal and conjunctival malignant melanoma cell lines.

Ralf A. Hilger, Mariam Scharifi, Michael Zeschnigk, Michaela Arndt, Max E. Scheulen, Jürgen Krauss, Michael Freistühler, Gordon Nareyeck, Henrike Westekemper

Pharmacokinetics of Sorafenib in Patients with Renal Impairment Undergoing Hemodialysis

Ralf A. Hilger, Heike Richly, Matthias Grubert, Susanne Kredtke, Dagmar Thyssen, Wilfried Eberhardt, Jörg Hense, Martin Schuler, Max E. Scheulen

Pharmacokinetic Study of the Humanized Anti-EGF-Receptor Monoclonal Antibody Nimotuzumab in Children/Adolescent and Adult Patients – final Results

Ralf A. Hilger, Susanne Kredtke, Ferdinand Bach, Dirk Strumberg, Gudrun Fleischhack

Activity of NAD(P)H oxidase in relation to genotypes: Comprehensive genetic mapping of single nucleotide polymorphisms (SNPs) in enzyme subunits

M. Hoffmann, M. Schirmer, J. Brockmüller

Anti-tumoral Activity of CLU-502 in NMRI Nude Mice – an update

Ulrike Koch, Dagmar Thyssen, Alexandra Heidemann, Susanne Kredtke, Siegfried Seeber, Ralf A. Hilger

Factors Influencing the Pharmacokinetics of High-Dose Carboplatin: A Population Approach

Andreas Lindauer, Christiane Eickhoff, Charlotte Kloft, Ulrich Jaehde

The identification of cancer-associated mutations in the tumour genomes of histopathological specimens

Katharina Schmücker, Bernd Herrmann, Susanne Hummel

Novel Method for the Identification of Protein-Drug Interactions

Michael Sefkow, Christian Dalhoff, Michael Hüben, Hubert Köster, Thomas Lenz, Peter Poot, Elmar Weinhold



The CESAR Annual Meeting is supported / sponsored by:

Graduiertenkolleg 1034 - Cancer Pharmacogenomics

Department of Clinical Pharmacology, Georg-August-University of Göttingen

Max-Planck-Institute for Experimental Medicine



Bayer HealthCare

Division Bayer-Schering Pharma



Boehringer
Ingelheim

Boehringer-Ingelheim Pharma